NASDAQ · Analyst Forecast

MetaVia Inc. (MTVA) Analyst Forecast

$1.24 NASDAQ: MTVA Market Cap $8.18M

Revenue and earnings estimates published by analysts covering MetaVia Inc. (MTVA), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For MetaVia Inc., the average estimate for 2030 earnings per share is $-1.40; 3 analysts contribute to these figures. These are forecasts published by analysts, not results.

Revenue forecast (USD millions)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

YearLowAverageHighAnalysts
2025$0$0$02
2026$0$0$02
2027$0$0$02
2028$0$0$03
2029$0$0$01
2030$0$0$01

Earnings per share forecast

YearLowAverageHighAnalysts
2025$-8.89$-8.89$-8.892
2026$-3.26$-2.52$-1.782
2027$-3.54$-2.37$-1.202
2028$-2.67$-1.66$-0.873
2029$-1.51$-1.51$-1.511
2030$-1.40$-1.40$-1.401

MetaVia Inc. (MTVA) forecast — frequently asked questions

What are analysts forecasting for MetaVia Inc.'s earnings?

The average analyst estimate for MetaVia Inc. (MTVA) earnings per share in 2030 is -1.40, with individual estimates between -1.40 and -1.40.

How much revenue is MetaVia Inc. expected to make?

Analysts forecast MetaVia Inc. (MTVA) revenue of $0 in 2030, based on 1 published estimates.

How many analysts cover MTVA?

3 analysts contribute estimates for MetaVia Inc. (MTVA). Thin coverage makes an average less reliable.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.